We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.
Community Guidelines: bit.ly/2MgAcio
MIMEDX is a pioneer and leader in the field of placental tissue. With more than a decade of helping clinicians manage chronic and hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical settings of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.
Exosome Diagnostics, Inc., a subsidiary of mdxhealth, is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases.
Exosomes are lipid bilayer covered microvesicles shed by solid tumors into body fluids, such as blood and urine. Exosomes contain nucleic acid profiles of cancers and other diseases. In published studies, Exosome Diagnostics has demonstrated the ability to extract exosomes from the blood and urine of patients, and to detect with high sensitivity and specificity key genes and gene mutations associated with a variety of cancers.